NSE: GAUDIUMIVF · BSE: 544709 · ISIN INE0P8B01020
Gaudium IVF and Women Health Limited stock analysis
Gaudium IVF and Women Health Limited ranks #735 in the TickerSutra evidence-ranked universe with a score of 61/100 and 85% data confidence. The latest captured fundamentals show ROCE of 29.3%, quarterly sales growth of 9.1% and quarterly profit growth of -42.0%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 29.3%
- Low debt/equity of 0.16×
- 33.2% three-year sales CAGR
- Institutional ownership is rising
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
- Operating margin has compressed materially
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹37cr | ₹14cr | ₹9cr | 37.0% |
| 2023 | ₹44cr | ₹20cr | ₹14cr | 46.0% |
| 2024 | ₹48cr | ₹19cr | ₹10cr | 41.0% |
| 2025 | ₹71cr | ₹29cr | ₹19cr | 41.0% |
| 2026 | ₹104cr | ₹38cr | ₹24cr | 36.0% |
| TTM | ₹106cr | ₹35cr | ₹23cr | 33.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Gaudium IVF and Women Health Limited has informed the Exchange regarding Proceedings of 11th Annual General Meeting of the Company held on Monday, September 28, 2026.
RoutineGaudium IVF and Women Health Ltd - 544709 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 29 Sept 2026Proceeding of 11th Annual General Meeting of the Company held on Monday, September 28, 2026.
RoutineGaudium IVF and Women Health Ltd - 544709 - Closure of Trading WindowBSE · 26 Sept 2026Gaudium IVF and Women Health Limited has informed the Exchange regarding the closure of Trading Window pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015
MANAGEMENT COMMENTARY
Signals from filed documents
PAT from continuing operations for Q1 27 stood at ₹1.8 crores as against ₹3.1 crores in Q1 FY26, a moderation of 42.27% year-on-year. Our balance sheet continues to remain robust and debt-light post the IPO, giving us the flexibility to fund our expansion plan with adequate financial cushion. Cash and bank balances as on 30th June stood at ₹8.12 crores against the borrowings of ₹6.74 crores and our consolidated debt-
To clarify, the Lucknow project will not be funded from the IPO proceeds earmarked for the 19 new IVF hubs and will be funded mainly through the company's internal accruals. As we scale up the network, our focus remains on maintaining the financial discipline that has defined the business, a debt-light structure, capital efficient asset-light hub and spoke roll- out, and steady margin expansion as new hubs mature and
So we are confident that by the end of the year we'll be achieving that growth. So by end of the year, we are confident of achieving 30% growth for FY27? And adjusted EBITDA margins similar to FY26 levels?
The pharmacy vertical supports our IVF patients through a curated, quality-assured supply of fertility medications and consumables, while our hospital operations extend into allied women health services including gynaecology, obstetrics, and minimally invasive procedures which go, you know, kind of hand-in-hand with IVF. While these segments carry structurally lower margins compared to our core IVF business, they pla
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…